(0.40%) 5 112.00 points
(0.78%) 38 680 points
(0.67%) 17 767 points
(0.49%) $79.34
(0.25%) $2.04
(-0.06%) $2 308.30
(-0.48%) $26.70
(0.84%) $970.70
(-0.39%) $0.929
(-0.96%) $10.89
(-0.41%) $0.795
(0.68%) $91.75
0.09% € 139.74
Live Chart Being Loaded With Signals
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...
Stats | |
---|---|
Volumen de hoy | 887.00 |
Volumen promedio | 3 343.00 |
Capitalización de mercado | 336.74B |
EPS | €0 ( 2024-04-15 ) |
Próxima fecha de ganancias | ( €0 ) 2024-07-16 |
Last Dividend | €1.190 ( 2023-08-25 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.25 |
ATR14 | €0.267 (0.19%) |
Volumen Correlación
Johnson & Johnson Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Johnson & Johnson Correlación - Moneda/Commodity
Johnson & Johnson Finanzas
Annual | 2023 |
Ingresos: | €85.16B |
Beneficio Bruto: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2023 |
Ingresos: | €85.16B |
Beneficio Bruto: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2022 |
Ingresos: | €94.94B |
Beneficio Bruto: | €63.85B (67.26 %) |
EPS: | €6.86 |
FY | 2021 |
Ingresos: | €93.78B |
Beneficio Bruto: | €63.92B (68.16 %) |
EPS: | €7.93 |
Financial Reports:
No articles found.
Johnson & Johnson Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.190 (N/A) |
€1.190 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.415 | 2008-02-22 |
Last Dividend | €1.190 | 2023-08-25 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 65 | -- |
Total Paid Out | €56.18 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.59 | -- |
Div. Sustainability Score | 3.76 | |
Div.Growth Potential Score | 5.82 | |
Div. Directional Score | 4.79 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SDF.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
BZ7A.F | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
KGX.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
TTK.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
DKG.DE | No Dividend Player | 2023-07-14 | Annually | 0 | 0.00% | |
MUB.DE | Ex Dividend Junior | 2023-08-11 | Annually | 0 | 0.00% | |
4PN.DE | Ex Dividend Knight | 2023-06-22 | Quarterly | 0 | 0.00% | |
XGR2.DE | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% | |
FDX.DE | Ex Dividend Knight | 2023-09-08 | Quarterly | 0 | 0.00% | |
PEP.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.453 | 1.500 | 0.949 | 1.424 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.572 | 1.500 | 4.76 | 7.14 | [0.1 - 1] |
payoutRatioTTM | 0.218 | -1.000 | 7.82 | -7.82 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 44.51 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 6.84 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.687 | 1.000 | 1.890 | 1.890 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.54 | 6.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.99 | 1.000 | 9.19 | 0 | [1 - 100] |
returnOnEquityTTM | 0.572 | 2.50 | 6.63 | 7.14 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 7.89 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.18 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.218 | 1.500 | 7.82 | -7.82 | [0 - 1] |
pegRatioTTM | -0.308 | 1.500 | -5.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.218 | 1.000 | 7.05 | 0 | [0.1 - 0.5] |
Total Score | 5.82 |
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico